International Journal of Hematology

, Volume 107, Issue 2, pp 194–200 | Cite as

Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography with gallium-67 scintigraphy in the initial clinical staging of diffuse large B-cell lymphoma

  • Masatoshi Sakurai
  • Takaaki Toyama
  • Taku Kikuchi
  • Jun Kato
  • Takayuki Shimizu
  • Yuya Koda
  • Daiki Karigane
  • Yusuke Yamane
  • Ryohei Abe
  • Rie Yamazaki
  • Tomonori Nakazato
  • Tadaki Nakahara
  • Masahiro Jinzaki
  • Shinichiro Okamoto
  • Takehiko Mori
Original Article
  • 82 Downloads

Abstract

Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) has been recommended as a complementary tool for the staging of various malignancies, including malignant lymphoma. PET findings often shift patients to higher stages and may affect treatment outcomes. In this study, we retrospectively compared staging and treatment outcomes of newly diagnosed diffuse large B-cell lymphoma (DLBCL) assessed by PET (n = 153) or gallium-67 scintigraphy (Ga) (n = 95). In total, Ga upstaged two (2.1%) of 95 patients, whereas PET upstaged 13 (8.5%) of 153 patients. Bone/bone marrow (15 vs. 4%, P = 0.01) and muscle lesion (5 vs. 0%, P = 0.03) were identified more frequently in the PET group than in the Ga group. The estimated 3-year overall and progression-free survival rates did not differ significantly in the two groups at any stage. However, patients with stage III disease tended to have better progression-free survival in the PET group than in the Ga group [92.3 (95% CI 56.6–98.9%) vs. 58.3% (95% CI 27.0–80.1%), P = 0.086]. These results suggest that PET has a greater potential in detecting musculoskeletal lesions of DLBCL as extranodal lesions than Ga, and may contribute to the optimal staging.

Keywords

Diffuse large B-cell lymphoma Positron emission tomography Gallium scintigraphy Staging 

Notes

Acknowledgements

The authors are indebted to Yuri Niizuma and Kaori Yanai for their skillful data management, and to Satomi Yamanaka for her excellent care of the patients and their families.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

References

  1. 1.
    Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer. 2002;94:879–88.CrossRefPubMedGoogle Scholar
  2. 2.
    Bednaruk-Młyński E, Pieńkowska J, Skórzak A, Małkowski B, Kulikowski W, Subocz E, et al. Comparison of positron emission tomography/computed tomography with classical contrast-enhanced computed tomography in the initial staging of Hodgkin lymphoma. Leuk Lymphoma. 2015;56:377–82.CrossRefPubMedGoogle Scholar
  3. 3.
    Wirth A, Seymour JF, Hicks RJ, Ware R, Fisher R, Prince M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma. Am J Med. 2002;112:262–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Chee KG, Nguyen DV, Brown M, Gandara DR, Wun T, Lara PN Jr. Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited. Arch Intern Med. 2008;168:1541–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985;312:1604–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Risum S, Høgdall C, Loft A, Berthelsen AK, Høgdall E, Nedergaard L, et al. Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian cancer? Gynecol Oncol. 2010;116:395–8.CrossRefPubMedGoogle Scholar
  7. 7.
    VanderWalde NA, Salloum RG, Liu TL, Hornbrook MC, O’Keeffe Rosetti MC, Ritzwoller DP, et al. Positron emission tomography and stage migration in head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2014;140:654–61.CrossRefPubMedGoogle Scholar
  8. 8.
    Baba S, Abe K, Isoda T, Maruoka Y, Sasaki M, Honda H. Impact of FDG-PET/CT in the management of lymphoma. Ann Nucl Med. 2011;25:701–16.CrossRefPubMedGoogle Scholar
  9. 9.
    Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol. 2011;29:1844–54.CrossRefPubMedGoogle Scholar
  10. 10.
    Gallamini A, Borra A. Role of PET in lymphoma. Curr Treat Options Oncol. 2014;15:248–61.CrossRefPubMedGoogle Scholar
  11. 11.
    Kostakoglu L, Cheson BD. Current role of FDG PET/CT in lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1004–27.CrossRefPubMedGoogle Scholar
  12. 12.
    Pelosi E, Pregno P, Penna D, Deandreis D, Chiappella A, Limerutti G, et al. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. Radiol Med. 2008;113:578–90.CrossRefPubMedGoogle Scholar
  13. 13.
    Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Carr R, Barrington SF, Madan B, O’Doherty MJ, Saunders CA, van der Walt J, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood. 1998;91:3340–6.PubMedGoogle Scholar
  15. 15.
    Shimizu T, Hatanaka K, Kaneko H, Shimada T, Imada K. Primary uterine diffuse large B-cell lymphoma (DLBCL) in a patient with prolonged insertion of intrauterine device (IUD). Int J Hematol. 2017;106:138–40.CrossRefPubMedGoogle Scholar
  16. 16.
    Kanaya M, Endo T, Hashimoto D, Endo S, Takemura R, Okada K. Diffuse large B-cell lymphoma with a bulky mass in the cranial vault. Int J Hematol. 2017;106:147–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Ishibashi N, Hata M, Mochizuki T, Ogawa K, Sugiura H, Takekawa Y, et al. Radiation therapy for primary breast lymphoma in male gynecomastia: a rare case report and review of the literature. Int J Hematol. 2016;104:519–24.CrossRefPubMedGoogle Scholar
  18. 18.
    Leighl NB. Positron emission tomography use and stage migration in lung cancer: a false sense of accomplishment? J Clin Oncol. 2012;30:2710–1.CrossRefPubMedGoogle Scholar
  19. 19.
    Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Govindan R. The effect of FDG-PET on the stage distribution of non-small cell lung cancer. J Thorac Oncol. 2008;3:135–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Chen YK, Yeh CL, Tsui CC, Liang JA, Chen JH, Kao CH. F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis. Clin Nucl Med. 2011;36:553–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Hong J, Lee Y, Park Y, Kim SG, Hwang KH, Park SH, et al. Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma. Ann Hematol. 2012;91:687–95.CrossRefPubMedGoogle Scholar
  22. 22.
    Muslimani AA, Farag HL, Francis S, Spiro TP, Chaudhry AA, Chan VC, et al. The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma. Am J Clin Oncol. 2008;31:409–12.CrossRefPubMedGoogle Scholar
  23. 23.
    Paes FM, Kalkanis DG, Sideras PA, Serafini AN. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. Radiographics. 2010;30:269–91.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  • Masatoshi Sakurai
    • 1
  • Takaaki Toyama
    • 1
  • Taku Kikuchi
    • 1
  • Jun Kato
    • 1
  • Takayuki Shimizu
    • 1
  • Yuya Koda
    • 1
  • Daiki Karigane
    • 1
  • Yusuke Yamane
    • 1
  • Ryohei Abe
    • 1
  • Rie Yamazaki
    • 1
  • Tomonori Nakazato
    • 1
  • Tadaki Nakahara
    • 2
  • Masahiro Jinzaki
    • 2
  • Shinichiro Okamoto
    • 1
  • Takehiko Mori
    • 1
  1. 1.Division of Hematology, Department of MedicineKeio University School of MedicineTokyoJapan
  2. 2.Department of RadiologyKeio University School of MedicineTokyoJapan

Personalised recommendations